company background image
CTXR

Citius Pharmaceuticals NasdaqCM:CTXR Stock Report

Last Price

US$1.36

Market Cap

US$198.8m

7D

3.0%

1Y

-9.9%

Updated

05 Feb, 2023

Data

Company Financials +

Citius Pharmaceuticals, Inc.

NasdaqCM:CTXR Stock Report

Mkt Cap: US$198.8m

CTXR Stock Overview

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy.

CTXR fundamental analysis
Snowflake Score
Valuation1/6
Future Growth3/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Citius Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Citius Pharmaceuticals
Historical stock prices
Current Share PriceUS$1.36
52 Week HighUS$2.01
52 Week LowUS$0.77
Beta1.2
1 Month Change54.95%
3 Month Change32.04%
1 Year Change-9.93%
3 Year Change29.52%
5 Year Change-59.28%
Change since IPO-90.93%

Recent News & Updates

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Dec 25
Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Recent updates

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Dec 25
Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK

Sep 28

Citius Pharmaceuticals GAAP EPS of -$0.06

Aug 11

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Aug 05
Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK

Jul 12

Citius Pharmaceuticals: Hoping For A Turnaround Strategy

Jul 05

Critical Care Biopharma - Citius Pharmaceuticals

Apr 13

Citius: 2022 Is A Year Of Catalysts

Mar 28

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Dec 04
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization

Sep 26

Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

Aug 28
Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

Citius: Halt For Superiority On The Horizon

Jun 15

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

May 15
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results

Apr 26

Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?

Dec 18
Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?

Shareholder Returns

CTXRUS PharmaceuticalsUS Market
7D3.0%-0.5%1.7%
1Y-9.9%4.6%-9.6%

Return vs Industry: CTXR underperformed the US Pharmaceuticals industry which returned 4.6% over the past year.

Return vs Market: CTXR matched the US Market which returned -9.6% over the past year.

Price Volatility

Is CTXR's price volatile compared to industry and market?
CTXR volatility
CTXR Average Weekly Movement11.2%
Pharmaceuticals Industry Average Movement11.5%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: CTXR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: CTXR's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200721Leonard Mazurhttps://www.citiuspharma.com

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Citius Pharmaceuticals, Inc. Fundamentals Summary

How do Citius Pharmaceuticals's earnings and revenue compare to its market cap?
CTXR fundamental statistics
Market CapUS$198.85m
Earnings (TTM)-US$33.64m
Revenue (TTM)n/a

0.0x

P/S Ratio

-5.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CTXR income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$33.64m
Earnings-US$33.64m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.23
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did CTXR perform over the long term?

See historical performance and comparison